Pharma Tech

AstraZeneca and insitro forge $1.5bn AI-powered cardiometabolic partnership

Oct 16, 2026, 10:24 AM

Read Full Article → AstraZeneca and insitro forge $1.5bn AI-powered cardiometabolic partnership

Translate article text

Choose a language and wait for the translated text.

This insitro deal sees AstraZeneca double down on its plans to enter the MASH market, which is expected to reach a value of $20.3bn in 2032.